Key Developments For Genomic Health, Inc.
Genomic Health, Inc. (GHDX.O) (Consolidated Issue listed on NASDAQ Global Market)
Genomic Health, Inc. Reaffirms FY 2009 Guidance-Conference Call
Genomic Health, Inc. announced that its third quarter 2009 results keeps the Company on target for fiscal 2009 to achieve previous revenue and loss guidance. According to Reuters Estimates, analysts are expecting the Company to report revenue of $152 million for fiscal 2009.
Genomic Health, Inc. Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential For Accurate Recurrence Risk Assessment In Early Stage Breast Cancer Patients
Genomic Health, Inc. announced the results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is a commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence. The study assessed 53 invasive breast carcinomas (19 well-, 19 moderately-, and 15 poorly-differentiated) to determine differences in gene expression between whole sections that contained biopsy cavities, enriched tumors where biopsy cavities were excluded and the dissected biopsy cavities. Standardized quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis for the 21 genes was performed. The results indicated that there was a statistically significant average increase in the Recurrence Score result for whole sections versus enriched tumors (5.35 Recurrence Score Units; p < .0001). There were also statistically significant differences in reference normalized gene expression between enriched tumor and whole sections in 12 of the 16 cancer-related genes. Additionally, biopsy cavities tended to have high-risk Recurrence Scores.
Genomic Health, Inc. Raises Low End Of Prior FY 2009 Revenue Guidance To A Range In Line With Estimates; Revises FY 2009 Earnings Guidance To A Range Above Estimates-Conference Call
Genomic Health, Inc. revised fiscal 2009 guidance for revenue to be between $150 and $160 million. The Company expects fiscal 2009 losses to be half of what they were a year ago. The Company reported net loss of $16 million in fiscal 2008. According to Reuters Estimates, analysts on an average were expecting the Company to report net loss of $12 million on revenue of $152 million for fiscal 2009.
Genomic Health, Inc. Reaffirms FY 2009 Guidance
Genomic Health, Inc. maintained fiscal 2009 guidance and expects total revenue of $148-$160 million and net loss of $14-$7 million. The Company expects continued progress in reimbursement to favorably impact product revenue; net loss to narrow in the second half of 2009 as compared with the first half of 2009. According to Reuters Estimates, analysts were expecting the Company to report revenues of $152 million and net income of $(11) million for the same period.
Genomic Health, Inc.'s Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
Genomic Health, Inc. announced results from a study which summarized the gene signatures identified by the Oncotype DX breast cancer test in a large number of male patients for whom the test was used to guide treatment with chemotherapy.
